Dupixent & Libtayo fuel growth despite volatility & Eylea biosimilar risks; margins to recover. Click for an REGN update.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results